ARCHIVES

NIH Director Varmus Names President of Sloan-Kettering, Succeeding Mark

This article is from The Cancer Letter archive.

Vol. 25 No. 39 | October 15, 1999

Download PDF Visit The Full Archive

Related Articles

Agreement Nears On New Guidelines For Center Grants

November 14, 1980

First-Line Tarceva Nearly Doubles PFS in EGFR-Activated Tumors

June 24, 2011

Demonstration project to yield useful data, Peter Bach says.

June 3, 2005

Regulatory Approvals: FDA expanded the approved use of Cyramza to include metastatic NSCLC

December 19, 2014

Evansvile CCOP Withdrawn, Cites Budget Cut, DR

September 9, 1983

FDA Approves Cyramza for Stomach Cancer; Zykadia in NSCLC; Lipiodol for HCC Imaging; And Cobas HPV Test for Primary Screening

April 25, 2014